by Perelman School of Medicine at the University of Pennsylvania A decade-spanning trial found that for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, two common methods of treatment actually do not have an impact on their long-term survival. The study, called PEXIVAS, was co-led by Peter A. Merkel, MD, MPH, chief of Rheumatology in the...
